Medicenna Therapeutics Business Summary

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company that generates value through the development and strategic out-licensing of its proprietary "Superkine" platforms, including BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Tumor-Masked SuperKines). The company’s business model focuses on high-unmet-need oncology segments, primarily leveraging its lead assets: MDNA11, a long-acting IL-2 super-agonist advancing toward registrational trials; bizaxofusp (MDNA55), a Phase 3-ready IL-4 targeted toxin for recurrent glioblastoma; and MDNA113, a PD-1 x IL-2 bispecific entering Phase 1 in 2026. Revenue is currently driven by milestone-based R&D partnerships and potential licensing fees, with a 2026 strategic priority of securing a global collaborator for bizaxofusp. In the competitive landscape of engineered cytokines, Medicenna positions itself as a "best-in-class" alternative to first-generation therapies from peers such as Alkermes, Sanofi, Roche, and Xilio Therapeutics, distinguishing its portfolio through superior receptor selectivity and a reduced toxicity profile. The company was co-founded by Dr. Fahar Merchant (President & CEO) and Rosemina Merchant (Chief Development Officer), a team of biotech veterans who previously led Protox Therapeutics and Avicenna Medica to successful exits. Dr. Merchant brings over 30 years of experience in biochemical engineering and serial entrepreneurship, while the executive leadership includes CFO Elizabeth Williams and Head of Clinical Development Dr. Martin Martin. Medicenna’s governance was recently strengthened in February 2026 with the appointments of strategic advisor Angelos Georgakis and legal expert Richard Sutin to the Board of Directors. The company maintains notable institutional backing from RA Capital Management and the Cancer Prevention and Research Institute of Texas (CPRIT), reflecting a strong pedigree in the immuno-oncology sector.